APA (7th ed.) Citation

Langley, R. G. B., Reich, K., Strand, V., Feldman, S. R., Paul, C., Gordon, K., . . . Augustin, M. (2020). Ixekizumab treatment and the impact on SF-36: Results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Quality of Life Research, 29(2), 369. https://doi.org/10.1007/s11136-019-02296-5

Chicago Style (17th ed.) Citation

Langley, Richard G. B., et al. "Ixekizumab Treatment and the Impact on SF-36: Results from Three Pivotal Phase III Randomised Controlled Trials in Patients with Moderate-to-severe Plaque Psoriasis." Quality of Life Research 29, no. 2 (2020): 369. https://doi.org/10.1007/s11136-019-02296-5.

MLA (9th ed.) Citation

Langley, Richard G. B., et al. "Ixekizumab Treatment and the Impact on SF-36: Results from Three Pivotal Phase III Randomised Controlled Trials in Patients with Moderate-to-severe Plaque Psoriasis." Quality of Life Research, vol. 29, no. 2, 2020, p. 369, https://doi.org/10.1007/s11136-019-02296-5.